• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    11/14/23 4:31:09 PM ET
    $ATNF
    $HROW
    $IVP
    $OWLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNF alert in real time by email

    Gainers

    • Theseus Pharmaceuticals (NASDAQ:THRX) stock increased by 34.1% to $2.87 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 142.2K shares, which is 116.8 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $125.1 million.
    • PaxMedica (NASDAQ:PXMD) stock increased by 19.87% to $2.05. Today's trading volume for this security ended up closing at 123.2K shares, which is 17.2 percent of its average volume over the last 100 days. The company's market cap stands at $2.0 million.
    • 180 Life Sciences (NASDAQ:ATNF) stock moved upwards by 17.94% to $0.55. Trading volume for this security closed at 1.5 million, accounting for 1128.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.2 million. As per the press release, Q3 earnings came out 3 days ago.
    • Exagen (NASDAQ:XGN) shares rose 9.58% to $1.6. The market value of their outstanding shares is at $26.9 million. The company's, Q3 earnings came out yesterday.
    • Renalytix (NASDAQ:RNLX) shares increased by 9.41% to $0.93. The company's market cap stands at $45.3 million. As per the news, the Q1 earnings report came out today.
    • Spero Therapeutics (NASDAQ:SPRO) stock increased by 8.1% to $1.2. The market value of their outstanding shares is at $63.2 million. As per the news, the Q3 earnings report came out yesterday.

    Losers

    • Harrow (NASDAQ:HROW) stock decreased by 22.1% to $10.0 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 179.7K shares, which is 34.7 percent of its average volume over the last 100 days. The company's market cap stands at $351.1 million. The company's, Q3 earnings came out yesterday.
    • Tenax Therapeutics (NASDAQ:TENX) stock fell 15.89% to $0.52. Today's trading volume for this security ended up closing at 22.1 million shares, which is 4198.0 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $12.4 million.
    • Beyond Air (NASDAQ:XAIR) stock declined by 13.8% to $1.75. This security traded at a volume of 87.4K shares come close, making up 25.7% of its average volume over the last 100 days. The company's market cap stands at $55.4 million. As per the press release, Q2 earnings came out yesterday.
    • Owlet (NYSE:OWLT) shares fell 12.55% to $5.63. The market value of their outstanding shares is at $47.7 million. The company's, Q3 earnings came out yesterday.
    • TRACON Pharma (NASDAQ:TCON) shares decreased by 10.15% to $0.19. Today's trading volume for this security ended up closing at 1.7 million shares, which is 84.6 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $5.9 million. The company's, Q3 earnings came out 3 days ago.
    • Inspire Veterinary (NASDAQ:IVP) stock declined by 9.8% to $0.5. The market value of their outstanding shares is at $5.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATNF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNF
    $HROW
    $IVP
    $OWLT

    CompanyDatePrice TargetRatingAnalyst
    Tenax Therapeutics Inc.
    $TENX
    3/17/2026$35.00Overweight
    Cantor Fitzgerald
    Owlet Inc.
    $OWLT
    12/9/2025Outperform
    William Blair
    Exagen Inc.
    $XGN
    9/11/2025$15.00Buy
    B. Riley Securities
    Tenax Therapeutics Inc.
    $TENX
    9/8/2025$20.00Overweight
    Piper Sandler
    Exagen Inc.
    $XGN
    7/30/2025$12.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Exagen Inc.
    $XGN
    7/23/2025$12.00Buy
    Craig Hallum
    Beyond Air Inc.
    $XAIR
    7/17/2025$11.00Buy
    D. Boral Capital
    Harrow Inc.
    $HROW
    7/11/2025$76.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ATNF
    $HROW
    $IVP
    $OWLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rich Stuart bought $50,792 worth of shares (5,000 units at $10.16), increasing direct ownership by 90% to 5,266 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/10/25 6:48:57 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rich Stuart bought $45,622 worth of shares (5,000 units at $9.12), increasing direct ownership by 940% to 2,766 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/5/25 5:46:32 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Giordano Christopher Thomas bought $20,000 worth of shares (2,605 units at $7.68) (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    11/20/25 6:38:51 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $HROW
    $IVP
    $OWLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Crawford Amanda

    4 - Owlet, Inc. (0001816708) (Issuer)

    3/27/26 9:50:09 PM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    New insider Mckhann Chas claimed ownership of 7,500 units of Restricted Stock Units (SEC Form 3)

    3 - EXAGEN INC. (0001274737) (Issuer)

    3/16/26 9:16:06 PM ET
    $XGN
    Medical Specialities
    Health Care

    Chief Financial Officer Black Jeffrey G. was granted 76,511 shares, increasing direct ownership by 29% to 343,953 units (SEC Form 4)

    4 - EXAGEN INC. (0001274737) (Issuer)

    3/16/26 7:17:29 PM ET
    $XGN
    Medical Specialities
    Health Care

    $ATNF
    $HROW
    $IVP
    $OWLT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $ATNF
    $HROW
    $IVP
    $OWLT
    SEC Filings

    View All

    SEC Form EFFECT filed by Tenax Therapeutics Inc.

    EFFECT - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

    4/2/26 12:15:29 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Beyond Air Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - Beyond Air, Inc. (0001641631) (Filer)

    4/1/26 4:30:07 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Harrow Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - HARROW, INC. (0001360214) (Filer)

    3/27/26 4:05:13 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $HROW
    $IVP
    $OWLT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)

    GARDEN CITY, N.Y., April 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced it has been awarded a national group purchasing agreement for inhaled nitric oxide therapy with a leading U.S. group purchasing organization (GPO). Effective April 1, 2026, the agreement allows participating member hospitals and health systems to access the LungFit® PH system. This new agreement builds on Beyond Air's existing relationships with leading U.S. GPOs, including Vizient and Premier, Inc., further expanding access to a broad network of

    4/1/26 9:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

    Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero's licensing partner, GSK announced the FDA had set the PDUFA date as June 18, 2026 Spero estimates cash and cash equivalents as of December 31, 2025 are sufficient to fund current operations into 2028 CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the fourth quarte

    3/26/26 4:05:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO

    GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi has resigned as Chief Executive Officer and stepped down from the Board of Directors, effective March 27, 2026, to pursue other opportunities. The Board of Directors has appointed Robert Goodman, the Company's current Chief Commercial Officer and Director, as Chief Executive Officer, effective today. For the past nine years, Mr. Lisi has led Beyond Air, guiding the development and launch of th

    3/26/26 4:05:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $ATNF
    $HROW
    $IVP
    $OWLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Tenax Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $35.00

    3/17/26 8:15:05 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Owlet

    William Blair initiated coverage of Owlet with a rating of Outperform

    12/9/25 8:52:06 AM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    B. Riley Securities initiated coverage on Exagen with a new price target

    B. Riley Securities initiated coverage of Exagen with a rating of Buy and set a new price target of $15.00

    9/11/25 8:42:21 AM ET
    $XGN
    Medical Specialities
    Health Care

    $ATNF
    $HROW
    $IVP
    $OWLT
    Leadership Updates

    Live Leadership Updates

    View All

    Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO

    GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi has resigned as Chief Executive Officer and stepped down from the Board of Directors, effective March 27, 2026, to pursue other opportunities. The Board of Directors has appointed Robert Goodman, the Company's current Chief Commercial Officer and Director, as Chief Executive Officer, effective today. For the past nine years, Mr. Lisi has led Beyond Air, guiding the development and launch of th

    3/26/26 4:05:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    180 Life Sciences Closes $425 Million Private Placement to Advance its Ethereum Treasury Strategy

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings Company plans to execute a differentiated yield generation program, with Company built for the Ethereum community, by the Ethereum community PALO ALTO, Calif., Aug. 4, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), (the "Company" or "ETHZilla"), has closed its previously announced private placement, raising $425 million in gross proceeds, before placement agent fees and offering expenses (the "Private Placement") through a private investment in public equity transaction ("PIPE") for the purchase and sale of common stock and pre-funded warrants, as applicable, at a purchase

    8/4/25 10:30:00 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exagen Inc. Appoints Chas McKhann to Board of Directors

    CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most recently, Mr. McKhann served as Board member, President and CEO of Silk Road Medical, and prior to that, Apollo Endosurgery, both Nasdaq-listed companies acquired by Boston Scientific, resulting in significant shareholde

    7/17/25 4:05:00 PM ET
    $XGN
    Medical Specialities
    Health Care

    $ATNF
    $HROW
    $IVP
    $OWLT
    Financials

    Live finance-specific insights

    View All

    Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

    CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update on Thursday, March 26, 2026, after market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare di

    3/18/26 4:05:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Owlet Reports Fourth Quarter and Full Year 2025 Results; Initiates 2026 Guidance

    Owlet, Inc. ("Owlet" or the "Company") (NYSE:OWLT), the pioneer of smart infant monitoring, today reports financial results for the fourth quarter and full year ended December 31, 2025. Owlet's President and Chief Executive Officer, Jonathan Harris, and Chief Financial Officer, Amanda Twede Crawford, will host a conference call to review the Company's results and provide a business update today, March 5, 2026, at 4:30 p.m. ET. Q4 2025 Financial Highlights: Q4 Revenue of $26.6 million, up 29.6% from Q4 2024 Q4 Gross Profit of $12.6 million, up $1.7 million from Q4 2024 despite tariff cost impacts; Q4 Gross Margin of 47.6% Q4 Operating Loss of $4.9 million, compared to operating lo

    3/5/26 4:05:00 PM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

    Fourth Quarter, Full-Year 2025 and Selected Highlights:  Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year periodFull-Year revenue of $272.3 million, a 36% increase over $199.6 million recorded in 2024GAAP net income of $6.6 million in Q4 2025, and net loss $5.1 million for 2025Adjusted EBITDA of $24.2 million in Q4 2025, and $61.9 million for 2025Generated $43.9 million of operating cash flow in 2025, versus $(22.2) million used in operations in 2024Cash and cash equivalents of $72.9 million as of December 31, 2025Full-year 2026 revenue guidance of $350 million to $365 million, including $133 million to $153 million in the first half of

    3/2/26 4:05:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $HROW
    $IVP
    $OWLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Exagen Inc.

    SC 13G/A - EXAGEN INC. (0001274737) (Subject)

    12/12/24 5:00:54 PM ET
    $XGN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    12/5/24 7:08:52 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care